The proceedings

The proceedings are Merck Sharp & Dohme LLC v. Halozyme, Inc., PGR2025-00050, on U.S. Patent 12,077,791 B2, and PGR2025-00053, on U.S. Patent 12,195,773 B2. Administrative Patent Judges Jeffrey N. Fredman, Susan L. C. Mitchell, and Cynthia M. Hardman sat on both panels. Administrative Patent Judge Mitchell wrote both opinions. Each decision is a final written decision dated November 18, 2026, entered under 35 U.S.C. 328(a). Merck Sharp & Dohme LLC is the petitioner and identifies itself as the real party in interest. Halozyme, Inc. is the patent owner and identifies itself and one other company as the real parties in interest.

U.S. Patent 12,077,791 B2 is titled "PH20 polypeptide variants with a modification at position 309 of the PH20 polypeptide and a method of making thereof." The PGR2025-00050 decision states that it issued on September 3, 2024, from U.S. Application 18/339,829, filed June 22, 2023. U.S. Patent 12,195,773 B2 is titled "PH20 polypeptide variants, formulations and uses thereof." The PGR2025-00053 decision states that it issued on January 14, 2025, from U.S. Application 18/659,215, filed May 9, 2024. Each decision describes its patent as drawn to modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity.

Institution

In PGR2025-00050, Merck requested post-grant review of claims 1-10 of the '791 patent. Halozyme statutorily disclaimed claims 4 and 5, leaving claims 1-3 and 6-10, and chose not to file a preliminary response. The Deputy Director, under authority the Director had delegated, determined not to exercise discretion to deny institution and referred the case to a Board panel. On November 19, 2025, the Board instituted trial of claims 1-3 and 6-10 (Paper 24). The decision states that the '791 patent was eligible for post-grant review and that at least one challenged claim was more likely than not unpatentable. 35 U.S.C. 324(a) uses that standard for institution of post-grant review. The oral hearing was July 23, 2026.

In PGR2025-00053, Merck requested post-grant review of claims 1-15 of the '773 patent. Halozyme statutorily disclaimed claim 4, leaving claims 1-3 and 5-15, and waived a preliminary response. The Director ruled on discretionary denial, and the case was referred to a Board panel. On November 19, 2025, the Board instituted trial of claims 1-3 and 5-15 (Paper 22). The decision states that the '773 patent was eligible for post-grant review and that at least one challenged claim was more likely than not unpatentable. The oral hearing was July 23, 2026.

In each proceeding the Board later denied Halozyme's motion to terminate. In PGR2025-00050 that order is Paper 77. Halozyme requested Director Review of that order (Paper 82), and the request was not considered because it was "outside the scope of Director Review." In PGR2025-00053 the order denying the motion is Paper 89, and Halozyme's request for Director Review of that order (Paper 80) was not considered for the same stated reason.

The '791 claim and the grounds

Claim 1 of the '791 patent, which the decision sets out as the sole independent claim, reads: "1. A modified PH20 polypeptide comprising an amino acid sequence, wherein: (a) at least 95% of the residues of the amino acid sequence of the modified PH20 polypeptide are identical to the residues in the amino acid sequence of SEQ ID NO: 35 when the sequence of the modified PH20 polypeptide is aligned at positions corresponding to the sequence set forth in the amino acid sequence of SEQ ID NO: 35 to maximize identical residues, and terminal gaps are treated as non-identical; (b) the amino acid sequence of the modified PH20 polypeptide comprises an amino acid modification at a position corresponding to position 309 with reference to amino acid positions set forth in the amino acid sequence of SEQ ID NO: 3; and (c) the modification at position 309 is a replacement selected from among E, G, H, L, M, N, Q, R, S, and T, and wherein the modified PH20 polypeptide exhibits increased hyaluronidase activity compared to the hyaluronidase activity of the polypeptide of SEQ ID NO: 3, measured under identical conditions."

The Board wrote that the challenged claims expressly require increased hyaluronidase activity compared to the polypeptide of SEQ ID NO: 3, and that it did not need to construe the claims further to decide written description and enablement. Merck's grounds, as the decision's table states them, were written description under 35 U.S.C. 112 for claims 1-3 and 6-10, and enablement under 35 U.S.C. 112 for claims 1-3 and 6-10. The Board adjusted that claim set to the claims remaining after the disclaimer of claims 4 and 5.

The '773 claim and the grounds

Claim 1 of the '773 patent, which the decision sets out as the sole independent claim, reads: "1. A soluble human PH20 polypeptide comprising: a modification at a position aligned to position 320 with reference to the amino acid positions set forth in SEQ ID NO: 3, and 19 or less additional amino acid modifications, after alignment with SEQ ID NO: 3 to maximize the number of identical residues, wherein: modifications comprise insertions, deletions, and replacements, and the modification at position 320 is a replacement selected from the group consisting of H, K, and R."

The Board found that the challenged claims, which recite a "soluble human PH20 polypeptide," require a polypeptide that has hyaluronidase activity. It reaffirmed that a "modified PH20 polypeptide" requires a polypeptide that has hyaluronidase activity, relying on its analysis in earlier post-grant reviews in the family, including PGR2025-00024.

The grounds table lists three grounds. Ground 1 is written description under 35 U.S.C. 112, claims 1-3 and 5-15. Ground 2 is enablement under 35 U.S.C. 112, claims 1-3 and 5-15. Ground 3 is obviousness under 35 U.S.C. 103 over the '429 patent and Chao, claims 1, 2, and 5-15. The decision identifies the '429 patent as U.S. Patent 7,767,429 B2, issued August 3, 2010, and Chao as Chao et al., Structure of Human Hyaluronidase-1, a Hyaluronan Hydrolyzing Enzyme Involved in Tumor Growth and Angiogenesis, 46 Biochemistry 6911-6920 (2007).

The judgments

Each decision states that the petitioner must prove unpatentability by a preponderance of the evidence. 35 U.S.C. 326(e). In PGR2025-00050 (Paper 88), the Board found that Merck had made that showing for written description and for enablement. On written description, the Board wrote that Halozyme "claims an immense number of mutations in the PH20 polypeptide, but provides insufficient guidance for a POSA as of 2011-2012 to determine which, if any, of the untested multiple mutated forms will retain hyaluronidase activity, much less exhibit increased activity as required by the instant claims." On enablement, the Board found that undue experimentation would have been required to enable the broad scope of the claims. The summary table lists claims 1-3 and 6-10 as shown unpatentable on both grounds. The order states that claims 1-3 and 6-10 of U.S. Patent 12,077,791 B2 are determined to be unpatentable.

In PGR2025-00053 (Paper 86), the summary table lists claims 1-3 and 5-15 as shown unpatentable for lack of written description and for lack of enablement, and lists claims 1, 2, and 5-15 as not shown unpatentable over the '429 patent and Chao. The Board found that Merck had not shown, by a preponderance of the evidence, that the combination of the '429 patent and Chao, with the knowledge and teaching described by two of Merck's declarants, demonstrates obviousness for the claims of the '773 patent, and wrote that Merck had not shown specific reasons to modify position 320 of the PH20 polypeptide. On written description, the Board wrote that Halozyme "claims an immense number of mutations in the soluble human PH20 polypeptide, but provides insufficient guidance for a POSA as of 2012 to determine which, if any, of the untested multiple mutated forms will retain hyaluronidase activity or solubility." On enablement, the Board found that undue experimentation would have been required to enable the broad scope of the claims. The order states that claims 1-3 and 5-15 of U.S. Patent 12,195,773 B2 are determined to be unpatentable. Both orders require a party seeking judicial review to comply with the notice and service requirements of 37 C.F.R. 90.2.

The New Jersey case

Both decisions state that the patents are subject to Halozyme, Inc. v. Merck Sharp & Dohme LLC f/k/a Merck Sharp & Dohme Corp., No. 2:25-cv-03179 (D.N.J.). The '791 decision lists the '773 patent and U.S. Patent 12,110,520 among the other patents in that case. The '773 decision lists the '791 patent and the '520 patent there as well. Each decision's table of related reviews includes PGR2025-00017, on U.S. Patent 12,110,520.

On August 6, 2026, Magistrate Judge Jose R. Almonte administratively stayed No. 2:25-cv-03179 pending the outcome of the patent reviews before the Patent Trial and Appeal Board and, if applicable, the Federal Circuit. That text order set a status conference for November 23, 2026, and called for a joint letter, not to exceed five pages, by November 16, 2026 (D.I. 65).

What to watch next

Watch for a notice of appeal. Under 35 U.S.C. 141(c), a party to a post-grant review who is dissatisfied with a final written decision under 35 U.S.C. 328(a) may appeal the Board's decision only to the United States Court of Appeals for the Federal Circuit. 37 C.F.R. 90.2 sets the notice and service requirements for that appeal. The case can end at any time, including by settlement or voluntary dismissal.